CagriSema Dual Pathway Metabolic Signaling Compound CagriSema combines two investigational molecules Cagrilintide (amylin analogue) and Semaglutide ( GLP 1 receptor agonist), designed to influence key metabolic and appetite regulating pathways. Current Combined GLP 1 amylin analog bests monotherapy for HbA1c drop, weight loss in diabetes Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination CagrilintideSemaglutide in Adults with Overweight or Obesity and Type 2 Diabetes New England Journal of Medicine